Overview

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Status:
Suspended
Trial end date:
2024-10-17
Target enrollment:
Participant gender:
Summary
CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute myeloid leukemia (AML).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Celgene
Collaborator:
AbbVie
Treatments:
Azacitidine
Venetoclax